Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.79 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.79 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.79 |
| ▸ | PAM | P19021 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | HPGD | P15428 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | FABP7 | O15540 | 1/20 | 0.51 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.51 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | LIPE | Q05469 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | NPY1R | P25929 | 1/20 | 0.48 |
| ▸ | NPY2R | P49146 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6784181 | 0.91 | ALDH1A1 (0.96) | ALDH1A1L3MBTL1MAPK1PAMKMT2A | |
| SCHEMBL361779 | 0.89 | ALDH1A1 (1.00) | ALDH1A1L3MBTL1MAPK1PAMKMT2A | |
| SCHEMBL4675591 | 0.86 | ALDH1A1 (0.79) | ALDH1A1L3MBTL1MAPK1PAMKMT2A | |
| SCHEMBL57331 | 0.86 | ALDH1A1 (0.85) | ALDH1A1L3MBTL1MAPK1PAMKMT2A | |
| SCHEMBL31245908 | 0.86 | ALDH1A1 (0.85) | ALDH1A1L3MBTL1MAPK1PAMKMT2A | |
| SCHEMBL27499661 | 0.85 | ALDH1A1 (0.92) | ALDH1A1L3MBTL1MAPK1PAMKMT2A | |
| SCHEMBL8117331 | 0.84 | ALDH1A1 (0.82) | ALDH1A1L3MBTL1MAPK1PAMKMT2A | |
| SCHEMBL7644741 | 0.83 | ALDH1A1 (0.54) | ALDH1A1L3MBTL1MAPK1SMN1; SMN2KMT2A | |
| SCHEMBL1724245 | 0.83 | ALDH1A1 (0.69) | ALDH1A1L3MBTL1MAPK1PAMKMT2A | |
| SCHEMBL27629121 | 0.83 | ALDH1A1 (0.74) | ALDH1A1L3MBTL1MAPK1PAMKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118598771-A | Oral small molecule P-selectin inhibitor, and preparation method and application thereof | 首都医科大学 | 2024-09-06 | — | — | CN | claimed |
| US-20250084081-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 | C4 THERAPEUTICS, INC. (US) | 2025-03-13 | — | — | US | disclosed |
| US-12157735-B2 | Compounds for targeted degradation of BRD9 | C4 THERAPEUTICS, INC. (US) | 2024-12-03 | — | — | US | disclosed |
| CN-118598771-A | Oral small molecule P-selectin inhibitor, and preparation method and application thereof | 首都医科大学 | 2024-09-06 | — | — | CN | disclosed |
| US-12049464-B2 | Compounds for targeted degradation of BRD9 | C4 THERAPEUTICS, INC. (US) | 2024-07-30 | — | — | US | disclosed |
| US-20240051953-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 | C4 THERAPEUTICS, INC. (US) | 2024-02-15 | — | — | US | disclosed |
| US-11691972-B2 | Compounds for targeted degradation of BRD9 | C4 THERAPEUTICS, INC. (US) | 2023-07-04 | — | — | US | disclosed |
| US-11691972-B2 | Compounds for targeted degradation of BRD9 | C4 THERAPEUTICS, INC. (US) | 2023-07-04 | — | — | US | disclosed |
| US-11691972-B2 | Compounds for targeted degradation of BRD9 | C4 THERAPEUTICS, INC. (US) | 2023-07-04 | — | — | US | disclosed |
| US-20230060334-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 | C4 THERAPEUTICS, INC. (US) | 2023-03-02 | — | — | US | disclosed |
| EP-2129654-A1 | NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR | Metabasis Therapeutics, Inc. (US) | 2009-12-09 | — | — | EP | disclosed |
| WO-2008098244-A1 | NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR | METABASIS THERAPEUTICS, INC. (US) | 2008-08-14 | — | — | WO | disclosed |
| EP-0687681-B1 | Immunogens for the production of cocaine-hydrolyzing catalytic antibodies | BARBER BRIAN H (CA) | 2001-12-05 | — | — | EP | disclosed |
| US-6017541-A | METHYL ECGONINE PHENYLPHOSPHONATES AS ANALOGUES OF TRANSITION STATES FOR THE HYDROLYSIS OF THE BENZOYL ESTER OF AN ECGONINE DERIVATIVE, NAMELY COCAINE, AND THEIR LINKING TO CARRIER PROTEINS FOR USE AS IMMUNOGENS | BARBER BRIAN H (CA) | 2000-01-25 | — | — | US | disclosed |
| US-5730985-A | METHYL ECGONINE PHENYLPHOSPHONATE AS CHEMICAL INTERMEDIATE OF COCAINE | GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 1998-03-24 | — | — | US | disclosed |
| US-5508437-A | APPETITE SUPPRESSANTS | HOFFMANN-LA ROCHE INC. (US) | 1996-04-16 | — | — | US | disclosed |
| EP-0687681-A1 | Immunogens for the production of cocaine-hydrolyzing catalytic antibodies | THE UNIVERSITY OF TORONTO (CA) | 1995-12-20 | — | — | EP | disclosed |
| US-5296608-A | Intermediates for analogs of tyrosine sulfate or tyrosine phosphate containing peptides | HOFFMAN-LA ROCHE INC. (US) | 1994-03-22 | — | — | US | disclosed |
| US-5182263-A | Appetite suppressants | HOFFMANN-LA ROCHE INC. (US) | 1993-01-26 | — | — | US | disclosed |
| EP-0339549-A2 | Tyr-peptide analogs | F. HOFFMANN-LA ROCHE AG (CH) | 1989-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230060334-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 | BRD9, BRD1, BRWD1 | ALDH1A1 4303/4885L3MBTL1 137/4885MAPK1 2633/4885 |
| US-12157735-B2 | Compounds for targeted degradation of BRD9 | BRD9, BRD1, BRWD1 | ALDH1A1 4303/4885L3MBTL1 137/4885MAPK1 2633/4885 |
| US-12049464-B2 | Compounds for targeted degradation of BRD9 | BRD9, BRD1, BRWD1 | ALDH1A1 4303/4885L3MBTL1 137/4885MAPK1 2633/4885 |
| US-20240051953-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 | BRD9, BRD1, BRWD1 | ALDH1A1 4303/4885L3MBTL1 137/4885MAPK1 2633/4885 |
| US-20250084081-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 | BRD9, BRD1, BRWD1 | ALDH1A1 4303/4885L3MBTL1 137/4885MAPK1 2633/4885 |
| US-11691972-B2 | Compounds for targeted degradation of BRD9 | BRD9, BRD1, BRWD1 | ALDH1A1 4230/4885L3MBTL1 557/4885MAPK1 2154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.